Patients should have grade 1 essential hypertension (140/90-159/99 mmHg), but free of history of any cardiovascular events, diabetes mellitus type 1 or 2 or rheumatoid arthritis.
Conditions
Interventions
Trade Name: Ascal(r) / carbasalate calcium
Pharmaceutical Form: Oral powder
Pharmaceutical form of the placebo: Oral powder
Route of administration of the placebo: Oral use
Sponsors
Leiden University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Essential hypertension, without treatment =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -Moderate or severe hypertension (>160/100) -Secondary hypertension -Personal history of cardiovascular events -Diabetes mellitus -Rheumatoid arthritis -Vasoactive medication -Any contraindication to use of aspirin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): -RAAS-activity represented by renin activity;Main Objective: To examine the effects of 100mg aspirin taken at bedtime on plasma renin activity in patients with grade 1 essential hypertension in primary prevention setting.;Secondary Objective: To examine the effects of 100mg aspirin taken at bedtime on (1) other determinants of RAAS-activity, (2) determinants of autonomous nervous activity and (3) determinants of COX-1 and COX-2 mediated activity as well as endothelial inflammation markers, in patients with grade 1 essential hypertension in primary prevention setting | — |
Countries
Netherlands
Outcome results
None listed